infectious complications & outcomes of patients with aml receiving treatment with hmas ± venetoclax
Published 1 year ago • 150 plays • Length 2:21Download video MP4
Download video MP3
Similar videos
-
1:34
single-center study evaluating the outcomes of patients with aml who relapsed after allosct
-
2:27
challenges with managing the high rates of infections seen in patients with aml
-
1:52
clinical features, complications, and outcomes of familial waldenström’s macroglobulinemia
-
2:27
predictors of outcomes in post-transplant patients with aml
-
1:41
how donor age impacts outcomes in patients with aml undergoing allosct
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
1:50
the challenge of treating elderly patients with aml with venetoclax plus azacitidine
-
4:48
the evolution of allosct in richter's transformation and its combination with biological agents
-
4:32
acute promyelocytic leukemia (apl) illness script video
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
3:08
selecting therapeutics for treating early relapses in multiple myeloma
-
1:46
tagraxofusp combined with azacitidine and venetoclax in the treatment of bpdcn and aml
-
1:59
phase i study of pevonedistat, azacitidine, and venetoclax in patients with r/r aml
-
1:14
the potential of uproleselan in patients with aml
-
5:36
venetoclax and azacitidine in mds patients
-
1:09
outcomes following haploidentical & cord blood transplantation in pediatric patients with aml
-
3:52
venetoclax & aml
-
2:27
emavusertib in combination with azacitidine and venetoclax in patients with aml
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml
-
2:45
continuity of care for patients with hematological predispositions to aml
-
3:23
patient characteristics and outcomes of allosct for bpdcn
-
2:25
venetoclax for aml